



SetPoint Medical Appoints Terry Bevirt as VP of Clinical Affairs

– Deep Expertise Will Guide SetPoint Bioelectronic Medicine Platform Clinical Programs –

Valencia, CA – July 31, 2017 – [SetPoint Medical](#), a clinical-stage biomedical technology company developing a bioelectronic therapy for chronic inflammatory diseases, announced today the appointment of Terry Bevirt as Vice President of Clinical Affairs. Ms. Bevirt brings more than 20 years of leadership experience in clinical research operations for pharmaceutical and biotechnology companies that range from large multinationals to startups.

At SetPoint, Ms. Bevirt will oversee clinical programs as the company advances its bioelectronic medicine approach for inflammatory diseases including rheumatoid arthritis and Crohn’s disease. She will report to Anthony Arnold, Chief Executive Officer of SetPoint Medical.

“SetPoint is pleased to welcome Terry, whose senior leadership expertise and successful history running pivotal clinical trials will be crucial to us as we conduct clinical trials with our new proprietary bioelectronic medicine device,” said [Anthony Arnold](#), Chief Executive Officer of SetPoint Medical. “Terry will work closely with our new Chief Medical Officer and other team leaders that make up a capable clinical team and ideally position SetPoint to develop and execute our clinical strategy through commercialization.”

SetPoint is developing a [novel proprietary bioelectronic medicine platform](#) to treat a variety of inflammation-mediated autoimmune diseases, using an implanted device to stimulate the vagus nerve, activating the body’s natural [Inflammatory Reflex](#) to produce a systemic anti-inflammatory effect. The emerging field of bioelectronic medicine aims to address unmet patient needs by delivering digital doses to modulate physiological circuits to treat diseases historically treated with drugs in a more targeted fashion.

Prior to joining SetPoint, Ms. Bevirt was Senior Director, Head of Clinical Operations at Armagen, where she managed operational strategy, study design feasibility, and the successful execution of clinical trials. Prior, she served as Therapeutic Area Planning and Operations Director at Amgen, where she provided strategic leadership and direction for study operations staff of 25, and she earlier held several other key clinical positions. Prior to Amgen, she held positions with Pharmacia, Affiliated Research Centers and Abbott Laboratories. She holds a B.S. in Medical Technology from the University of Wisconsin at Milwaukee and is a Certified Clinical Research Associate.

About SetPoint Medical

[SetPoint Medical](#) is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer

patients and providers an [alternative](#) treatment for rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy.

SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body's natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human proof-of-concept trial in rheumatoid arthritis in *Proceedings of the National Academy of Sciences* (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline's Action Potential Venture Capital Limited and Boston Scientific. For more information, visit www.setpointmedical.com.

#

Media Contact:

Kathryn Morris

O: 845-635-9828

M: 914-204-6412

kathryn@brightpointny.com